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Treatment of lung cancer had evolved during the last decade with the introduction of
new chemotherapeutic regimens and targeted therapies. However, the maximum benefit
reached after first-line therapy is limited by the cumulative toxicity of platinum drugs and
the subsequent deterioration in performance status in a high percentage of patients who
end up receiving not more than one line of treatment. Maintenance therapy had been intro-
duced and evaluated in many large randomized trials showing a delay in tumor progression
and an improvement in overall survival.This effective strategy should be taken into account
when discussing the initial treatment plan and tailored according to the preferences of both
patients and physicians.
Keywords: maintenance, pemetrexed, erlotinib, gefitinib, bevacizumab, lung cancer, docetaxel
INTRODUCTION
Standard first-line treatment for patients who are negative for the
EGFR mutation and ALK rearrangement consists of platinum-
based chemotherapy (1). The optimal number of cycles had been
determined after Park et al. compared four to six cycles of treat-
ment showing non-inferiority in terms of overall survival and thus,
making four cycles a currently accepted standard (2).
During the past decade, research from different work groups
has focused on finding alternative strategies to improve tumor
response and extend survival.
The limited benefit from extending platinum-based chemother-
apy beyond four cycles as well as the cumulative toxicities of these
regimens leading to worsening of the quality of life (QoL) (2–4)
had led to the re-emergence of a relatively new concept based on
maintaining the response in patients who attain tumor control
during first-line induction treatment.
Therefore, cytotoxic agents and molecularly targeted agents
have been extensively evaluated in this setting and two practical
applications of maintenance therapy have evolved: continuation
maintenance and switch maintenance.
Maintenance therapy has potential advantages and inconve-
niences. Although many large randomized studies have shown that
maintenance therapy is associated with a delay in tumor progres-
sion and an improvement in overall survival, prolonging therapy
in a palliative intent also significantly increases the burden of med-
ical interventions to a patient, prohibits the patient from having an
often desired treatment holiday and may also increase treatment
related toxicities, which may have a detrimental impact on QoL.
This mini review will expose the issues related to main-
tenance therapy and discuss a personalized approach to the
implementation of such strategies in clinical practice.
CONTINUATION MAINTENANCE
Continuation maintenance refers to the continuation of one or
more non-platinum agents, initially used during induction, until
progression. This approach allows the discontinuation of plat-
inum compounds known to cause cumulative toxicity that often
becomes clinically meaningful after four to six doses of these drugs.
It also has the advantage of continuing an agent for which tolerance
has been defined in the induction phase of the treatment.
In 2006, Sandler et al. published the results of the ECOG 4599
trial, which showed that continuing bevacizumab (Bev) beyond six
cycles of paclitaxel (Pac)/carboplatin (Carbo)/Bev added 2 months
improvement in OS compared to six cycles of Carbo/Pac alone
(HR, 0.79, p= 0.003) (5). Similarly, in 2009, Pirker et al. demon-
strated in the FLEX study, that maintenance with cetuximab after
chemotherapy with cisplatin/vinorelbine/cetuximab significantly
improved OS (11.3 vs. 10.1 months; HR, 0.87, p= 0.044) com-
pared to cisplatin/vinorelbine alone (6). It is not clear whether
the benefit of bevacizumab or cetuximab in these studies is
from their integration of the induction phase, the maintenance
phase or both. Nonetheless, the design of these trials revived
the concept of adapting maintenance as an appropriate clinical
strategy.
Gemcitabine was evaluated in three randomized trials. CECOG
(7) and IFCT-GFPC 0502 (8) met their primary endpoint show-
ing longer PFS but with no significantly improved OS. These
trials show interesting trends toward an increase in overall sur-
vival although this interpretation is limited by the small sample
size of these trials. In a third trial, Belani et al. failed to demon-
strate any advantage of maintenance gemcitabine on PFS and OS.
These negative results have been attributed to the fact that most
patients (64%) had a poor performance status (PS 2) at random-
ization in contrast to most other maintenance trials where most
of the patients were PS 0 or 1 (9).
More recently, continuation maintenance with pemetrexed
(pem) has been evaluated in two large randomized studies. In
the PARAMOUNT trial, continuation pem after four cycles of
induction with cisplatin/pem demonstrated significant improve-
ment in PFS (4.1 vs. 2.8 months; HR, 0.62; p< 0. 0001) and OS
(16.9 vs. 14 months; HR, 0.78; p= 0.019) (10). In 2009, Patel
et al. combined pem and bev as continuous maintenance in a
phase II study. Their strategy was safe and resulted in a promising
14.1 months median OS (11). Maintenance with pem and bev was
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thereafter tested in three major phase III studies. In AVAPERL,
there was a 3.6 months improvement in PFS in the Pem/Bev arm
compared to the Bev arm, and OS benefit was similar as that
reported in PARAMOUNT although the sample size was too small
to demonstrate statistical significance (19.8 vs. 15.9 months, HR,
0.88, p= 0.32) (12).
Although not a maintenance trial per se, PointBreak com-
pared the ECOG 4599 regimen Pac/Carbo/Bev followed by Bev to
Pem/Carbo/Bev followed by maintenance with Pem/Bev. Despite
the fact that this study did not show significant improvement in
OS (median OS, 12.6 vs. 13.4 months; p= 0.949) and a slight
advantage in PFS favoring the pemetrexed containing regimen
(median PFS, 6.0 vs. 5.6 months; HR, 0.83; p= 0.012), the study
results highlighted different toxicity profiles between the pacli-
taxel and pemetrexed containing regimens that may lead to a
better treatment selection (13). Fatigue and thrombocytopenia
were more frequent in the pem arm and neutropenia, neuropathy,
and alopecia more frequent in the paclitaxel arm.
The ongoing ECOG 5508 study may better define the optimal
choice of maintenance agent after pac/carbo/bev as it random-
izes patients for maintenance after induction into three arms: Bev
alone, Pem alone, or combined Pem-Bev (Table 1).
SWITCH MAINTENANCE
Switch maintenance is the introduction of an additional, poten-
tially non-cross-resistant agent, immediately after completion of
first-line chemotherapy in patients who achieved an objective
response or a stable disease. This strategy focuses on the early
integration of drugs that have been shown to be useful in the sec-
ond line setting and in this regard can be seen as “early second
line” therapy. This exposes the patient to new toxicity that needs
to be addressed before choosing such a strategy.
The first pivotal trial to report benefit with a cytotoxic agent
using this strategy was presented by Fidias et al. who random-
ized 309 patients with advanced NSCLC who did not progress
after front-line treatment with four cycles of carbo/gemcitabine
to receive immediate docetaxel maintenance therapy vs. delayed
docetaxel at disease progression. The study showed a significant
3 months improvement in PFS and a non-statistically significant
2.5 months increase in OS in favor of the “immediate” docetaxel
arm, with no increase in toxicity or decrease in QOL. Even though
the patients in the delayed arm were carefully assessed and followed
and that docetaxel was available to all of these patients, 37.2% of
the patients in this arm did not receive docetaxel due to a rapid
disease progression or a rapid PS decline (14).
JMEN is a phase III trial that evaluated maintenance pem vs.
BSC in 633 non-progressive stage IIIB/IV patients after non-pem
containing platinum-doublet chemotherapy. The pemetrexed arm
showed significantly improved PFS (4.3 vs. 2.6 months; HR, 0.5,
p< 0.0001) and OS (13.4 vs. 10.6 months; HR, 0.79; p= 0.012).
Subgroup analysis based on histology showed that the improve-
ment in PFS (4.5 vs. 2.6 months; HR, 0.44; p= 0.0001) and OS
(15.5 vs. 10.3 months; HR, 0.70; p= 0.002) was restricted to
patients with tumors having a non-squamous histology (72.5%
of the population) (15). In this trial, there was a limited access to
pem in the BSC arm, as only 18% of patients were treated with
this drug, thus creating a subsequent imbalance in interpreting the
benefit of pem as a highly active drug in this particular population.
After showing an OS benefit in second and third line setting
for advanced NSCLC (16), erlotinib was evaluated as a switch
Table 1 | Key studies addressing continuous maintenance.
Reference (study name) N (pts) Maintenance arms PFS (mo) HR pValue OS (mo) HR pValue
Sandler et al. (5) 850 Bevacizumab 6.2 0.66 <0.001 12.3 0.79 0.003
(ECOG 4599) Observation 4.5 10.3
Pirker et al. (6) 850 Cetuximab 4.8 0.943 0.39 11.3 0.871 0.044
(FLEX) Placebo 4.8 10.1
Brodowicz et al. (7) 206 Gemcitabine 3.6 <0.001 13 0.195
(CECOG) BSC 2.0 11
Perol et al. (8) 464 Gemacitabine 3.8 0.56 <0.001 12.1 0.89 0.3867
(IFCT-GFPC 0502) Observation 1.9 10.8
Belani et al. (9) 255 Gemacitabine 3.9 0.58 8.0 0.97 0.84
Observation 3.8 9.3
Paz-Ares et al. (10) 539 Pemetrexed 4.1 0.62 <0.001 13.9 0.78 0.0195
(PARAMOUNT) BSC 2.8 11.0
Barlesi et al. (12) 253 Pem/Bev 10.2 0.5 <0.001 19.8 0.88 0.32
(AVAPERL) Bev 6.6 15.9
Patel et al. (13) 590 Pem/Bev 6.0 0.83 0.012 12.6 1 0.949
(Point break) Bev 5.6 13.4
PFS=progression-free survival; OS=overall survival; BSC=best supportive care; HR= hazard ratio; Bev=bevacizumab; Pem= pemetrexed.
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maintenance therapy in SATURN, a large phase III trial that ran-
domized 889 patients who did not progress after four cycles of a
platinum doublet, to erlotinib or placebo. There was a modest but
statistically significant improvement in PFS (3 vs. 2.8 months; HR
0.71, p< 0.0001) and OS (12 vs. 11 months; HR, 0.81, p= 0.0088).
Subgroup analyses showed larger treatment benefit in terms of OS
in patients with stable disease (HR, 0.72) after induction than in
responders (HR, 0.94). Progression-free survival was significantly
higher in patients with EGFR activating mutations (HR, 0.23)
than in patients EGFR WT (HR, 0.78) but a survival difference
could not be demonstrated in these subgroups (17). In a similar
fashion to the JMEN trial, erlotinib was not widely available to
patients in the placebo arm and only 21% of these patients were
actually treated with erlotinib. Similar results were seen in the
Erlotinib maintenance arm of the smaller IFCT-GFPC 0502 study
mentioned earlier, with a 1 month improvement in PFS but no
statistically significant change in OS (8). Following these positive
results, Johnson et al. studied the combination of bev and erlotinib
in maintenance. In the ATLAS trial, 1160 patients received first-
line platinum-based chemotherapy with bev, 768 patients had an
objective response or SD, and were randomized to receive bev
with erlotinib vs. bev alone. This trial showed 1 month improve-
ment in PFS (4.8 vs. 3.7 months, HR 0.72, p= 0.0012) for patients
in the combination maintenance arm but a non-statistically sig-
nificant improvement in OS (14.4 vs. 13.3 months; HR, 0.92;
p= 0.5341) (18).
The EORTC Lung Cancer Group and the Italian Lung Cancer
Project evaluated maintenance with gefitinib vs. placebo in 173
patients who did not progress after four cycles of platinum-based
chemotherapy. PFS was better in the treatment arm (4.1 vs.
2.9 months; HR, 0.61; p= 0.0015) but with no statistically signif-
icant improvement in OS (10.9 vs. 9.4 months; HR, 0.83; p= 0.2)
(19). The INFORM trial, an Asian phase III trial, tested gefitinib in
a similar setting in 296 patients (79 EGFR-mut). PFS was sig-
nificantly higher in the gefitinib arm (4.8 vs. 2.6 months; HR,
0.42; p< 0.0001) with more benefit EGFR-mut subgroup (HR,
0.17) compared to EGFR WT (HR, 0.87). An OS benefit was not
shown (18.7 vs. 16.9 months; HR, 0.84; p= 0.2608) (20). Finally,
the West Japan Thoracic Oncology Group 0203 phase III trial
compared prolonged chemotherapy with 6 cycles of a platinum
doublet to a short course of 3 cycles followed by gefitinib mainte-
nance in 604 patients. PFS was statistically better favoring gefitinib
maintenance (4.6 vs. 4.3 months; HR, 0.68; p< 0.001) but no sig-
nificant difference in OS was found (13.7 vs. 12.9 months; HR,
0.86; p= 0.11) (21) (Table 2).
DISCUSSION
Maintenance therapy,whether in switch or continuation approach,
has proved to be beneficial in patients with advanced NSCLC who
have received up to four cycles of a platinum-containing regimen.
Despite much debate regarding the results of the different stud-
ies and the reserved improvement in survival, Pemetrexed and
Erlotinib are already approved and used for maintenance in many
countries.
ARGUMENTS AGAINST MAINTENANCE
In dealing with a population of patients with a non-curable disease,
improvements in overall survival and QoL remain the primary
Table 2 | Key studies evaluating switch maintenance.
Reference (study name) N (pts) Maintenance arms PFS (mo) HR pValue OS (mo) HR pValue
Fidias et al. (14) 309 Immediate 5.7 0.0001 12.3 0.0853
Docetaxel
Delayed 2.7 9.7
Docetaxel
Ciuleanu et al. (15) 663 Pemetrexed 4.3 0.5 <0.0001 13.4 0.79 0.012
(JMEN) Placebo 2.6 10.6
Cappuzzo et al. (17) 889 Erlotinib 3.0 0.71 <0.0001 12.0 0.81 0.0088
(SATURN) Placebo 2.8 11.0
Perol et al. (8) 310 Erlotinib 2.9 0.69 0.003 11.4 0.87 0.3043
(IFCT-GFPC 0502) Observation 1.9 10.8
Kabbinavar et al. (18) 768 Bev/Erlotinib 4.8 0.72 0.0012 14.4 0.92 0.5341
(ATLAS) Bevacizumab 3.7 13.3
Gaafar et al. (19) 173 Gefitinib 4.1 0.61 0.0015 10.9 0.83 0.2
(EORTC08021-LCP01/03) Placebo 2.9 9.4
Zhang et al. (20) 296 Gefitinib 4.8 0.42 <0.0001 18.7 0.84 0.26
(INFORM) Placebo 2.6 16.9
Takeda et al. (21) 604 Gefitinib 4.6 0.68 <0.001 13.7 0.86 0.11
(WJTOG 0203) Observation 4.3 12.9
PFS=progression-free survival; OS=overall survival; BSC=best supportive care; HR=hazard ratio; Bev=bevacizumab; Pem=pemetrexed.
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objective. Symptomatic patients who begin induction therapy
with a platinum doublet for lung cancer are often looking for-
ward to a symptom free and drug free holiday. In this regard,
many patients who obtain a meaningful symptomatic response
to induction are not enthusiastic about adding on more ther-
apy, especially if maintenance therapy is discussed after induction.
Compared to continuation maintenance, switch maintenance has
the added inconvenience of exposing the patient to new toxicities
not encountered during induction. The interpretation of many
trials is also bound with controversy. In particular, the absence of
broad availability of pemetrexed in the JMEN trial or erlotinib in
SATURN limits the interpretation of any small OS gain observed
in these studies as these drugs are now widely available in many
countries, particularly in the second line setting. The question now
becomes as to whether these agents are better given before radio-
logical or clinical progression (“early second line”) or at the time
of clear progression.
ARGUMENTS FOR MAINTENANCE
The current data appear even more compelling for continua-
tion maintenance, especially for non-squamous and EGFR-mut
patients. The PARAMOUNT trial has shown a PFS and an OS
benefit for continuation pem in responding and stable disease
patients. As used in this trial, limiting therapy to four cycles of cis-
platin therapy decreases platin-related toxicities and the absence
of new drug exposure limits the risk of new unexpected toxic-
ities. Considering a median time to progression of 6–12 weeks
in many observation arms of maintenance strategy trials, delay-
ing progression is a clinically meaningful endpoint to many
patients.
The case for switch maintenance is more debatable. For reasons
described above, the apparent OS benefit for switching to erlotinib
or pemetrexed may be associated to study design not relevant to
current practice. Nonetheless, progression in the placebo arms is
often very rapid as reported in trials where radiological and clin-
ical follow up is frequent. Leaving patients without treatment can
thus expose them to rapid and early progression, often leading
to a decline in performance status and inability to receive further
therapy. As the biggest benefit in the JMEN and SATURN trial
appears to be in patients obtaining no more than SD to induction
therapy, it may be hypothesized that these patients may obtain
more benefit from an earlier initiation of second line therapy. As
such, it seems reasonable to consider switch therapy to patients
that did not obtain palliative benefit from induction therapy in
an attempt to better alleviate symptoms and prevent symptomatic
progression.
Some patients are identified as having an actionable mutation
during induction chemotherapy. The ideal timing of the begin-
ning of targeted therapy in this particular situation is still a matter
of debate. It seems reasonable to pursue induction chemotherapy
in these patients, particularly if they are responding and tolerating
treatment well. On the other hand, switching to a specific targeted
agent is appropriate if induction is poorly tolerated or if symptoms
are poorly controlled. Targeted agents, for instance EGFR and ALK
inhibitors, are associated with rapid improvement in symptoms in
patients harboring sensitive mutations to these agents.
CONCLUSION
Maintenance therapy has shown effectiveness in delaying progres-
sion in many studies as well as prolonging overall survival in some
settings. Appropriate clinical decisions involve early discussions
of these options with potentially eligible patients. Factors that
may impact in the final decision to initiate maintenance include
tumor histology, clinical and radiological response to induction,
tumor mutations, and most importantly patient choice. Further
improvements in treatment and patient selection will most likely
arise with the improved refinement of the molecular diagnosis of
lung cancers.
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